Clinical trial • Phase III • Gastroenterology

ROPIVACAINE HYDROCHLORIDE for Inguinal hernia

Phase III trial of ROPIVACAINE HYDROCHLORIDE for Inguinal hernia.

Overview

Trial Therapeutic Area
Gastroenterology
Trial Disease
Inguinal hernia
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
06-08-2024
First CTIS Authorization Date
05-11-2024

Trial design

Randomised, placebo control using nacl 0.9 solution (natriumchloride 0,9% fresenius kabi / nacl 0.9 solution). dose/schedule not specified in the provided documents. Phase III trial across 3 sites in Finland.

Randomised
Yes
Comparator
Placebo control using NaCl 0.9 solution (Natriumchloride 0,9% Fresenius Kabi / NaCl 0.9 solution). Dose/schedule not specified in the provided documents.
Target Sample Size
200

Eligibility

Recruits 200 Vulnerable population not selected. Participants must be able to give written informed consent and have adequate Finnish language literacy; minors are excluded (age under 18 years)..

Pregnancy Exclusion
Pregnancy or breast-feeding, aim of becoming pregnant during the study,
Vulnerable Population
Vulnerable population not selected. Participants must be able to give written informed consent and have adequate Finnish language literacy; minors are excluded (age under 18 years).

Inclusion criteria

  • {"criterion_text":"- Able to give a written informed consent\n- Aged 18 years or older at screening\n- Diagnosed with Inguinal hernia scheduled for open inguinal hernia surgery\n- Adequate Finnish language literacy\n- Unilateral surgery"}

Exclusion criteria

  • {"criterion_text":"- Surgery that is planned to be performed under general or spinal anesthesia\n- Allergy or hypersensitivity to study medications or their ingredients\n- Pregnancy or breast-feeding, aim of becoming pregnant during the study,\n- Inability to provide written informed consent\n- Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study\n- A history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements\n- Prior or concurrent malignancy\n- Surgery that was not planned as day surgery\n- Bilateral surgery\n- Additional surgery to inguinal hernioplasty\n- Age under 18 years\n- Inability to give informed consent\n- Patient refusal\n- Chronic pain or prior opioid medication\n- Psychiatric disorder as defined by: medication used"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Equivalent morphine consumption in the perioperative period and after surgery, divided in: Intraoperative period, the immediate postoperative period, defined as the time between discharge from the operating room and discharge from the hospital and seven postoperative days","definition_or_measurement_approach":"Morphine consumption measured in defined time windows: intraoperative period; immediate postoperative period (time between discharge from the operating room and discharge from the hospital); and seven postoperative days."}

Secondary endpoints

  • {"endpoint_text":"- postoperative pain, as defined by numerical rating scale (NRS), patient opinion of the efficacy of the pain treatment, postoperative nausea and vomiting (PONV), as defined as use of postoperative nausea medications, use of rescue analgesia, rescue hospitalization, intra- and postoperative durations, intraoperative anesthetic methods, analysis of patient flow and, anesthesiologic and surgical complications, depression and anxiety as measured by BDI and STAI queries","definition_or_measurement_approach":"Postoperative pain measured by numerical rating scale (NRS); PONV defined as use of postoperative nausea medications; depression and anxiety measured by BDI and STAI questionnaires; other items captured as stated (patient opinion, rescue analgesia use, rescue hospitalization, durations, complications, etc.)."}

Recruitment

Planned Sample Size
200
Recruitment Window Months
171
Consent Approach
Written informed consent required from each participant. A subject information sheet and informed consent form for adults (L1_SIS and ICF adults) are listed among documents. Participants must have adequate Finnish language literacy. Minors are excluded; no assent process described.

Geography

Total Number Of Sites
3
Total Number Of Participants
200

Finland

Earliest CTIS Part Ii Submission Date
03-04-2024
Latest Decision Or Authorization Date
06-11-2024
Processing Time Days
217
Number Of Sites
3
Number Of Participants
200

Sites

Site Name
Tampere University Hospital
Department Name
Anestesia ja tehohoito
Principal Investigator Name
Maija-Liisa Kalliomäki
Principal Investigator Email
maija-liisa.kalliomaki@pirha.fi
Contact Person Name
Maija-Liisa Kalliomäki
Site Name
Pirkanmaan hyvinvointialue (Valkeakoski)
Department Name
Anestesiologia ja tehohoito
Principal Investigator Name
Aki Lumme
Principal Investigator Email
aki.lumme@pirha.fi
Contact Person Name
Aki Lumme
Contact Person Email
aki.lumme@pirha.fi
Site Name
Pirkanmaan hyvinvointialue (Tampere Hatanpää)
Department Name
Anestesiologia ja tehohoito
Principal Investigator Name
Juha Virman
Principal Investigator Email
juha.virman@pirha.fi
Contact Person Name
Juha Virman
Contact Person Email
juha.virman@pirha.fi

Sponsor

Primary sponsor

Full Name
Pirkanmaan hyvinvointialue
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Finland

Investigational products

Investigational Product Name
Ropivacaine hydrochloride Kabi 7,5 mg/ml injekcinis tirpalas
Active Substance
ROPIVACAINE HYDROCHLORIDE
Modality
Small molecule
Routes Of Administration
INJECTION
Route
INJECTION
Authorisation Status
Authorised (marketingAuthorisationNumber: LT/1/22/5005/002)
Maximum Dose
112.5 mg
Investigational Product Name
Natriumchloride 0,9% Fresenius Kabi oplossing voor infusie
Active Substance
SODIUM CHLORIDE
Modality
Small molecule
Routes Of Administration
INJECTION
Route
INJECTION
Authorisation Status
Authorised (marketingAuthorisationNumber: BE197127)
Maximum Dose
30 ml
Investigational Product Name
NaCl 0.9 solution
Modality
Small molecule

Related trials

Other published trials that may interest you.